Emerging Trends in Cell Banking (Technical Insights)

Emerging Trends in Cell Banking (Technical Insights)

Trends in Master and Working Cell Baking

RELEASE DATE
29-Dec-2014
REGION
Global
Research Code: D567-01-00-00-00
SKU: LS00181-GL-TR_17321
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00181-GL-TR_17321
$3,950.00
DownloadLink
ENQUIRE NOW

Description

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of most operational challenges. Indeed, cultured cells are frequently used to generate monoclonal antibodies (MAbs), enzymes, or substrates to be then utilized in other types of tests, such as ligand binding and enzymatic assays, thereby requiring distinct characterization and control measures to guarantee functional reliability over time.

The extreme sensitivity of cellular components to different chemical and physical elements and the possibility of alterations in the proteome expression profiles hold significant importance in assessing biopharmaceutical products. Therefore, the need for homogeneous, stable cell banks capable of safeguarding starting cellular material is substantial to perform reliable cell-based assays. Master and working cell banks (MCBs and WCBs) are established with the aim to provide a continuous source of viable cells that allow to generate accurate results for specific test methods.

This research service brings out the emerging trends in MCBs and WCBs on a global scale, through a detailed description of:
The technology capability and value chain; analysis of global technology trends.
An impact analysis of major drivers, restraints, and challenges influencing the growth of cell banks by timeframes.
An assessment of technology adoption and development, by region, demand side analysis, and recommendations for technology/product/services developers.
An evaluation of scenario modelling and emerging opportunities in MCBs and WCBs, technology management strategies and technology application roadmap.
A list of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.

Table of Contents

Research Scope

Research Methodology

Key Findings

Technology Overview

Technology Process Overview

Technology Value Chain

Technology Capability

Technology Capability

Technology Capability

Technology Capability

Market Impact of Key Innovations

Market Impact of Key Innovations

Market Impact of Technology

Market Impact of Technology

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Technology Adoption Cycle

Scenario Modelling and Emerging Opportunities

Demand Side Analysis

Demand Side Analysis

Biophramas are increasing their partnerships with CMOs, for storing their proprietary cell lines and the development of novel cell lines.

Company Profiles (continued)

Company Profiles (continued)

Company Profiles (continued)

Company Profiles (continued)

Company Profiles (continued)

Key Contacts

Key Contacts (continued)

Key Contacts (continued)

Key Contacts (continued)

Patents

Patents (continued)

DSD–Government Healthcare Expenditure (Billion USD)

DSD–Pharmaceutical R&D Expenditure as a Percentage of Pharmaceutical Market

DSD–Pharmaceutical R&D Expenditure (Million USD)

DSD–Total Healthcare Expenditure (Billion USD)

DSD–Venture Capital Investment in Biotech R&D (Million USD)

Legal Disclaimer

Who is Frost & Sullivan

What Makes Us Unique

TEAM Methodology

Our Global Footprint 40+ Offices

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of most operational challenges. Indeed, cultured cells are frequently used to generate monoclonal antibodies (MAbs), enzymes, or substrates to be then utilized in other types of tests, such as ligand binding and enzymatic assays, thereby requiring distinct characterization and control measures to guarantee functional reliability over time. The extreme sensitivity of cellular components to different chemical and physical elements and the possibility of alterations in the proteome expression profiles hold significant importance in assessing biopharmaceutical products. Therefore, the need for homogeneous, stable cell banks capable of safeguarding starting cellular material is substantial to perform reliable cell-based assays. Master and working cell banks (MCBs and WCBs) are established with the aim to provide a continuous source of viable cells that allow to generate accurate results for specific test methods. This research service brings out the emerging trends in MCBs and WCBs on a global scale, through a detailed description of: The technology capability and value chain; analysis of global technology trends. An impact analysis of major drivers, restraints, and challenges influencing the growth of cell banks by timeframes. An assessment of technology adoption and development, by region, demand side analysis, and recommendations for technology/product/services developers. An evaluation of scenario modelling and emerging opportunities in MCBs and WCBs, technology management strategies and technology application roadmap. A list of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.
More Information
No Index Yes
Podcast No
Author Cecilia Van Cauwenberghe
WIP Number D567-01-00-00-00
Is Prebook No